Wim Tamminga

Wim Tamminga currently serves as the Chief Executive Officer at CTC Netherlands since March 2024. Prior to this role, Tamminga worked at QPS, LLC from December 2010 to March 2024, where responsibilities included overseeing the Early Phase Clinical business and leading the Phase 1 unit in Groningen, The Netherlands, with a focus on early phase trials. Previous positions include Senior Director of Early Development Services at PRA International, along with roles in data strategy and support at both PRA International and Pharma Bio Research. Tamminga holds a PhD in Pharmacology and Pharmacogenetics from the University of Groningen, completed between 1997 and 2001.